These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7814880)

  • 61. In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma.
    Elliott BE; Carlow DA; Ivimey L; Arnold M; Hampton N; Bosman P
    Cancer Res; 1987 Sep; 47(18):4915-23. PubMed ID: 2441856
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tumor growth alters macrophage responsiveness to macrophage colony-stimulating factor during reactivity against allogeneic and syngeneic MHC class II molecules.
    Walker TM; Burger CJ; Elgert KD
    Immunol Invest; 1993; 22(6-7):463-76. PubMed ID: 8262568
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Significance of class 1 and class 2 major histocompatibility complex antigens: help to allogeneic K and D antigens does not involve I recognition.
    Swain SL
    J Immunol; 1981 Jun; 126(6):2307-9. PubMed ID: 6164727
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunogenic variants of a murine fibrosarcoma induced by mutagenesis: requirement of viable cells for antigen-specific cross-protection.
    LeGrue SJ; Simcik WJ; Frost P
    Cancer Res; 1987 Aug; 47(16):4413-6. PubMed ID: 3607772
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differential antigen presentation in tumor immunity.
    Schatten S; Drebin JA; Granstein RD; Greene MI
    Fed Proc; 1984 Jun; 43(9):2460-4. PubMed ID: 6327399
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.
    Baskar S; Azarenko V; Garcia Marshall E; Hughes E; Ostrand-Rosenberg S
    Cell Immunol; 1994 Apr; 155(1):123-33. PubMed ID: 8168141
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes.
    Chen PW; Ullrich SE; Ananthaswamy HN
    J Leukoc Biol; 1994 Oct; 56(4):469-74. PubMed ID: 7930943
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.
    Ostrand-Rosenberg S; Clements VK; Thakur A; Cole GA
    J Immunogenet; 1989; 16(4-5):343-9. PubMed ID: 2639907
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adoption of tumor immunity: role of the major histocompatibility complex.
    Poupon MF; Payelle B; Lespinats G
    J Immunol; 1981 Jun; 126(6):2342-6. PubMed ID: 6971896
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice.
    Freland S; Chambers BJ; Andersson M; Van Kaer L; Ljunggren HG
    J Immunol; 1998 Jan; 160(2):572-9. PubMed ID: 9551890
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
    Shiloni E; Karp SE; Custer MC; Shilyansky J; Restifo NP; Rosenberg SA; Mulé JJ
    Cancer Immunol Immunother; 1993 Oct; 37(5):286-92. PubMed ID: 8402732
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection.
    Mongini C; Sánchez Lockhart M; Waldner CI; Alvarez EM; Gravisaco MJ; Roig MI; Hajos SE
    Br J Cancer; 1996 Jul; 74(2):258-63. PubMed ID: 8688332
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunotherapy of MHC class I-deficient tumors.
    Reiniš M
    Future Oncol; 2010 Oct; 6(10):1577-89. PubMed ID: 21062157
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Rat adenocarcinoma 13762 expresses tumor rejection antigens but tumor-bearing animals exhibit tumor-specific immunosuppression.
    Frey AB; Appleman LJ
    Clin Immunol Immunopathol; 1993 Nov; 69(2):223-33. PubMed ID: 8403560
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Helper factor(s) generated by tumor-immune rats for lymphoproliferative responses to syngeneic tumor cells.
    Hollingsworth MA; Evans DL
    J Natl Cancer Inst; 1984 Jun; 72(6):1357-63. PubMed ID: 6233443
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Differential expression of the H-2Dk MHC class-I antigen and tissue inhibitor of metalloproteinases in metastatic and nonmetastatic T-10 fibrosarcoma cells.
    Har-Vardi I; Gopas J; Rager-Zisman B; Hammerling GJ; Segal S; Aboud M
    Invasion Metastasis; 1992; 12(5-6):301-8. PubMed ID: 1298741
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunological characteristics of immunogenic variants induced in the MCA-F murine fibrosarcoma using 1-methyl-3-nitro-1-nitrosoguanidine, 5-aza-2'-deoxycytidine, or ultraviolet radiation.
    Simcik W; Frost P; LeGrue SJ
    Cancer Res; 1989 Aug; 49(15):4192-8. PubMed ID: 2472875
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Facilitation of macrophage-mediated destruction of allogeneic fibrosarcoma cells by tumor-enhancing IgG 2 in vitro.
    Cruse JM; Whitten HD; Lewis GK; Watson ES
    Transplant Proc; 1973 Mar; 5(1):961-7. PubMed ID: 4695960
    [No Abstract]   [Full Text] [Related]  

  • 79. Cytokines and suppressor macrophages cause tumor-bearing host CD8+ T cells to suppress recognition of allogeneic and syngeneic MHC class II molecules.
    Walker TM; Yurochko AD; Burger CJ; Elgert KD
    J Leukoc Biol; 1992 Dec; 52(6):661-9. PubMed ID: 1464737
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells.
    Qiu G; Goodchild J; Humphreys RE; Xu M
    Cancer Immunol Immunother; 1999 Dec; 48(9):499-506. PubMed ID: 10602887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.